Crossmark

Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density

Crossref DOI link: https://doi.org/10.1007/s00198-018-4460-6

Published Online: 2018-03-10

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Naylor, K. E. https://orcid.org/0000-0002-1002-0772
Bradburn, M.

Paggiosi, M. A.

Gossiel, F.

Peel, N. F. A.

McCloskey, E. V.

Walsh, J. S.

Eastell, R.
License Information

Text and Data Mining valid from 2018-03-10
More Information

Article History

Received: 23 October 2017

Accepted: 18 February 2018

First Online: 10 March 2018

Compliance with ethical standards

:

: NP has received speaker’s honoraria and funding to attend educational events from Warner-Chilcott, Eli Lilly, Amgen, GSK and Prostrakan and consultancy fees from Internis Pharma and Eli Lilly. JW has received speaker’s honoraria from Eli Lilly, grant funding from Alexion and Immunodiagnostic Systems, research drug and kits from Eli Lilly, Prostrakan (Kyowa Kirin), Consilient and Biomedica, consulting fees from Shire and Mereo Biopharma. EM has received speaker’s honoraria and/or research funding and/or advisory board funding from Warner-Chilcott, Merck, Amgen, GSK, Bayer, Consilient Healthcare, Hologic, Eli Lilly, Novartis, Pfizer, Servier, Wyeth and Roche. RE has received grant funding from Warner-Chilcott and the National Institute for Health Research (NIHR) and consultancy funding from Warner-Chilcott, Roche, Immunodiagnostic Systems and Merck. KN, MB, MP and FG have nothing to disclose.